452311-42-1

Basic information

• Product Name: 2,3-Quinoxalinediamine,N-methyl-(9CI)
• Synonyms: 2,3-Quinoxalinediamine,N-methyl-(9CI);N-METHYLQUINOXALINE-2,3-DIAMINE;N*3*-Methyl-quinoxaline-2,3-diamine;N2-methylquinoxaline-2,3-diamine
• CAS NO: 452311-42-1
• Molecular Formula: C9 H10 N4
• Molecular Weight: 174.2
• Product Categories: PIPERIDINE
• Mol File: 452311-42-1.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 337.638°C at 760 mmHg
• Flash Point: 157.998°C
• Appearance: /
• Density: 1.322g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.758
• CAS DataBase Reference: 2,3-Quinoxalinediamine,N-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Quinoxalinediamine,N-methyl-(9CI)(452311-42-1)
• EPA Substance Registry System: 2,3-Quinoxalinediamine,N-methyl-(9CI)(452311-42-1)

Safety Data

• Hazardous Substances Data: 452311-42-1(Hazardous Substances Data)

Usage

Chemical Family

Quinoxaline

Structure

It features a quinoxaline ring system with an additional amine group and a methyl group attached to the nitrogen atom.

Utility

Medicinal Chemistry: Commonly used in medicinal chemistry.
Organic Synthesis: Employed in organic synthesis.

Potential Applications

Drug Synthesis: Can serve as a building block for synthesizing drug molecules.
Pharmacophore: Can act as a pharmacophore in drug design.

Interest for Further Study

Properties and Characteristics: Specific properties and characteristics make it intriguing for further research.
Potential Therapeutic Agents: Suggests potential use in developing new drugs and therapeutic agents.

InChI:InChI=1/C9H10N4/c1-11-9-8(10)12-6-4-2-3-5-7(6)13-9/h2-5H,1H3,(H2,10,12)(H,11,13)

Upstream product

• 2213-63-0 2,3-dichloroquinoxaline 
• 34117-90-3 2-amino-3-chloroquinoxaline 
• 74-89-5 methylamine 

Relevant articles and documents

Imidazo[1,2-a]quinoxalines: Synthesis and cyclic nucleotide phosphodiesterase inhibitory activity

A group of imidazo[1,2-a]quinoxalines have been synthesised from quinoxaline by condensation of an appropriate haloester or intramolecular cyclisation of a keto moiety on an intracyclic nitrogen atom. The reactivity of the heterocycle was explored through diverse reactions such as electrophilic substitution, lithiation and halogen-metal exchange to give access to a new series of derivatives. Confirmation of their structure was mainly performed by NMR, after careful assignment of the signals in comparison to previous attributions made on the parent imidazo[1,2-a]quinoxaline and discussion of available data in the literature. The cyclic nucleotide phosphodiesterase inhibitor activity of some of these derivatives has been assessed on isoenzymes type III and type lV. Compound 15, 4-(methylamino)imidazo[1,2-a]quinoxaline-2-carbonitrile, exhibited potent relaxant activity on smooth muscle, with a potency similar to the one measured with SCA 40, its structural analogue in the imidazo[1,2-a]pyrazine series.